Navigation Links
Watson Files FDA Application for Generic LYBREL(R)
Date:3/13/2008

- Paragraph IV Patent Challenge Underway -

CORONA, Calif., March 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its Levonorgestrel and Ethinyl Estradiol tablets, USP (0.09 mg/0.02 mg) extended-cycle oral contraceptive product prior to the expiration of patents owned by Wyeth. Watson's Levonorgestrel and Ethinyl Estradiol product is a generic version of Wyeth's LYBREL(R) (levonorgestrel and ethinyl estradiol) tablets which is indicated for the prevention of pregnancy.

Wyeth filed suit against Watson on March 12, 2008 in the U.S. District Court, District of Delaware, seeking to prevent Watson from commercializing its product prior to the expiration of U.S. patent number 6,500,814. Wyeth's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner. Based on available information, Watson believes it may be the first applicant to file an ANDA for LYBREL(R) and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking st
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
2. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
3. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
5. Watson Receives FDA Approval for Generic Accuneb(R)
6. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
7. CryoCor Files Patent Infringement Lawsuits Against CryoCath
8. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
11. Roche Files IND for Second Genmab Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/14/2014)... Cells regulate protein functions in a wide variety of ... instant, a protein can take on another form and ... proteins that fold wrongly can cause serious diseases such ... proteins also have a tendency to "infect" other molecules ... amyloid fibrils or plaques. These amyloids can damage cells ...
(Date:9/12/2014)... Advancing the front lines of research ... biological threats is the mission of an international ... and the Georgian National Academy of Sciences, and ... Security Programme of the North Atlantic Treaty Organization ... series, the event is titled “Nanotechnology to Aid ...
(Date:9/11/2014)... 2014 RURO, Inc., a leading ... solutions and sample management solutions provider, announces the ... work on the most recent version of its ... already seen mass adoption, especially from multi-license environment ... 5.0 brought an entirely new User Interface and ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3Measuring modified protein structures 2Measuring modified protein structures 3Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Limfinity® Version 5.1 Available 2
... Ohio -- In the quest for smaller, faster computer ... the exotic physics of the small. The problem: ... been equally exotic. That is, until now. ... to make quantum devices using technology common to the ...
... 15 Today, Formatech, Inc. announced that ... HIV/AIDS vaccine will be the first clinical candidate that is ... run is scheduled to be completed in January 2010. ... aseptically fill and finish one lot of the vaccine for ...
... 15 SIRO Clinpharm, a global Contract Research Organization (CRO) ... announced expansion of its Clinical Trials Supplies facility in Mumbai, ... pharmaceutical and biotech companies for storage and distribution of clinical ... , "We opened our clinical trials supplies warehouse ...
Cached Biology Technology:Quantum computer chips now 1 step closer to reality 2Quantum computer chips now 1 step closer to reality 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 2Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 4SIRO Clinpharm Strengthens its Clinical Trials Supplies Service Offering in India 2
(Date:9/15/2014)... Globally, cardiovascular disease (CVD) claims 17 million lives each ... additional 9.4 million. 1 New research presented by ... in Montpellier, France on September 15, 2014, suggests that ... , At the Milk and Dairy Products ... and risk for hypertension and CVD was examined by ...
(Date:9/15/2014)... the need for vitamin E and how much is ... levels of this essential micronutrient are especially critical for ... or may become pregnant. , A lifelong proper intake ... often complicated by the fact that this nutrient is ... alone. It has been estimated that only a tiny ...
(Date:9/12/2014)... DUBLIN, Ireland , September 12, 2014 ... and Markets ( http://www.researchandmarkets.com/research/trs4c7/global ) has announced ... Lock Industry Report 2014" report to ... Fingerprint Lock Industry Report 2014 is a ... state of the global fingerprint lock industry. ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3Global Fingerprint Lock Industry Report 2014 2
... Spanish . Losses of managed honey bee ... 2009 to April 2010, according to a survey conducted by ... Service (ARS). Beekeepers identified starvation, poor weather, and weak colonies ... their operations. This is an increase from overall losses ...
... cognitive decline and for preventing Alzheimer,s diseasemental stimulation, ... studied over the years. However, an independent panel ... Health determined that the value of these strategies ... of decline or disease hasn,t been demonstrated in ...
... research team has taken a major step forward in understanding ... immune response by combining nanotechnology and cell biology. T cells ... response to infection. Christopher Cairo and his team ... cell response is switched on. Cairo looked at the molecule ...
Cached Biology News:Survey reports latest honey bee losses 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 3U Alberta-led team studies T cell activation with nanoparticles 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: